Liquidia Corporation's Upcoming Q2 2025 Financial Results
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company based in Morrisville, is making significant strides in the field of innovative therapies for patients suffering from rare cardiopulmonary diseases. The company is set to report its financial results for the second quarter of 2025 on Tuesday, August 12, 2025. This announcement is part of their commitment to keeping investors informed about their progress and developments.
Webcast to Discuss Financial Results
To coincide with this important financial update, Liquidia Corporation will host a live webcast at 8:30 a.m. Eastern Time, which will provide insights into the company’s performance and strategic direction. Analysts, investors, and interested parties will have the opportunity to gain a deeper understanding of the company’s financial health and future prospects during this session.
How to Access the Webcast
The webcast will be available on Liquidia's official website, allowing viewers to tune in from the comfort of their homes or offices. Post-event, a rebroadcast will also be accessible, ensuring that those who are unable to attend the live session can still catch up on the critical information shared.
About Liquidia Corporation
Liquidia Corporation is not just about numbers; they are committed to impacting patients' lives through the development of groundbreaking therapies. Their core focus revolves around treating pulmonary hypertension and other associated conditions using their proprietary PRINT Technology. This technology has facilitated the creation of YUTREPIA™ (treprostinil) inhalation powder, particularly targeting individuals living with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD).
Innovative Products in Development
In addition to YUTREPIA™, Liquidia is actively working on L606, an innovative sustained-release formulation of treprostinil intended for administration twice daily via a next-generation nebulizer. Moreover, the company markets a generic version of Treprostinil Injection, further establishing its presence in the PAH treatment market.
Investor Relations and Media Contacts
For investors eager to learn more about Liquidia's upcoming financial disclosures or any inquiries, Jason Adair, the Chief Business Officer, is available at 919.328.4350. He can also be reached through email at jason.adair@liquidia.com. Any media inquiries can be directed to Patrick Wallace, the Director of Corporate Communications, at 919.328.4383, or via email at patrick.wallace@liquidia.com.
Frequently Asked Questions
What is the date for Liquidia's Q2 financial report?
Liquidia Corporation will report its Q2 2025 financial results on August 12, 2025.
How can I access the financial results webcast?
The webcast can be accessed through Liquidia's official website where it will also be archived for later viewing.
What is Liquidia Corporation known for?
Liquidia Corporation specializes in developing innovative therapies for rare cardiopulmonary diseases using its proprietary PRINT Technology.
Who should I contact for investor inquiries?
For investor-related questions, you can contact Jason Adair at 919.328.4350 or via email at jason.adair@liquidia.com.
What is YUTREPIA™?
YUTREPIA™ is a treprostinil inhalation powder developed by Liquidia for treating pulmonary arterial hypertension (PAH) and other pulmonary conditions.
